Search results for "82"

showing 10 items of 2220 documents

Genomic evolution of bacterial populations under coselection by antibiotics and phage

2017

Bacteria live in dynamic systems where selection pressures can alter rapidly, forcing adaptation to the prevailing conditions. In particular, bacteriophages and antibiotics of anthropogenic origin are major bacterial stressors in many environments. We previously observed that populations of the bacterium Pseudomonas fluorescens SBW25 exposed to the lytic bacteriophage SBW25Φ2 and a noninhibitive concentration of the antibiotic streptomycin (coselection) achieved higher levels of phage resistance compared to populations exposed to the phage alone. In addition, the phage became extinct under coselection while remaining present in the phage alone environment. Further, phenotypic tests indicate…

0301 basic medicineMutation rateantibiotic resistancemedicine.drug_class030106 microbiologyAntibioticsBiologyPseudomonas fluorescensmedicine.disease_causeMicrobiologyEvolution MolecularBacteriophage03 medical and health sciencesAntibiotic resistanceMutation RateDrug Resistance BacterialGeneticsmedicineBacteriophagesexperimental evolutionSelection GeneticEscherichia coliEcology Evolution Behavior and Systematics2. Zero hungerExperimental evolutionta1182biology.organism_classificationsublethal antibiotic concentrationsAnti-Bacterial AgentsPhenotypeLytic cyclephage resistanceStreptomycinta1181phage phi-2Genome BacterialBacteria
researchProduct

Involvement of Thyroid Hormones in Brain Development and Cancer

2021

Simple Summary Development and function of the mammalian brain clearly require precise regulation of gene expression at both the transcriptional and post-transcriptional level. Thyroid hormones have been recognized to play a fundamental role in these processes, by acting at multiple levels and in different brain cell types, through direct effects on transcription, mediated by nuclear receptors, and also by triggering transduction pathways at the plasma membrane. At the same time, due to their effects on proliferation, differentiation, and cell metabolism, thyroid hormones may have a critical role in different kinds of cancer, including brain cancer. Abstract The development and maturation o…

0301 basic medicineNervous systemCancer ResearchNuclear and membrane TH receptorsThyroid hormonesReviewBiologyBrain cancer03 medical and health sciences0302 clinical medicineSettore BIO/10 - BiochimicamedicineSettore BIO/06 - Anatomia Comparata E CitologiaRC254-282Regulation of gene expressionDeiodinasesThyroidNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerTH transportersmedicine.diseaseBrain developmentChromatinCell biology030104 developmental biologymedicine.anatomical_structureOncologyNuclear receptorTH carriersThyroid function030217 neurology & neurosurgeryHormoneCancers
researchProduct

The Role of SVZ Stem Cells in Glioblastoma

2019

As most common primary brain cancer, glioblastoma is also the most aggressive and malignant form of cancer in the adult central nervous system. Glioblastomas are genetic and transcriptional heterogeneous tumors, which in spite of intensive research are poorly understood. Over the years conventional therapies failed to affect a cure, resulting in low survival rates of affected patients. To improve the clinical outcome, an important approach is to identify the cells of origin. One potential source for these are neural stem cells (NSCs) located in the subventricular zone, which is one of two niches in the adult nervous system where NSCs with the capacity of self-renewal and proliferation resid…

0301 basic medicineNervous systemCancer ResearchSubventricular zoneReviewBiologylcsh:RC254-282brain tumor stem cells03 medical and health sciences0302 clinical medicineCancer stem cellmedicineProgenitor cellneural stem cellstherapyNeurogenesisglioblastomasubventricular zoneCancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseNeural stem cellnervous system diseasesneurogenesis030104 developmental biologymedicine.anatomical_structurenervous systemOncology030220 oncology & carcinogenesisCancer researchStem cellCancers
researchProduct

Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases

2018

Background: No data is available on the molecular background of the extra-nodal extension (ENE) of lymph node metastasis (LN) in colorectal cancer (CRC). Methods: A series of 22 ENE-positive CRCs was considered and three samples per case were selected (the primary CRC, an ENE-negative and an ENE-positive metastatic LN). Samples (n=66) were analysed by immunohistochemistry for PD-L1, CD4, CD8, CD68 and CD80. Fifteen out of twenty-two cases were further profiled through a hotspot multigene mutational custom panel, including 164 hotspot regions of AKT1, APC, BRAF, CTNNB1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, PTEN and TP53 genes. Results: A significantly higher percentage of CD4-, CD8- and CD68-pos…

0301 basic medicineNeuroblastoma RAS viral oncogene homologCancer ResearchColorectal cancerBiomarkers; Colorectal cancer; Extranodal extension; Metastasis; Oncology; Genetics; Cancer ResearchPDGFRAmedicine.disease_causelcsh:RC254-282not knownMetastasisMetastasis03 medical and health sciences0302 clinical medicineExtranodal extensionGeneticsmedicinePTENlcsh:QH573-671Biomarkers; Colorectal cancer; Extranodal extension; Metastasisneoplasmsbiologybusiness.industrylcsh:Cytologymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrimary tumorColorectal cancerdigestive system diseases030104 developmental biologyOncology030220 oncology & carcinogenesisbiology.proteinCancer researchImmunohistochemistryKRASbusinessPrimary ResearchBiomarkersCancer Cell International
researchProduct

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis

2019

Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) have demonstrated efficacy with chemotherapy (CT) as second line treatment for metastatic colorectal cancer (mCRC). The right sequence of the treatments in all RAS (KRAS/NRAS) wild type (wt) patients has not precisely defined. We evaluated the impact of aforementioned targeted therapies in second line setting, analyzing efficacy and safety data from phase III clinical trials. We performed both direct and indirect comparisons between anti-EGFR and anti-VEGF. Outcomes included disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS), overall su…

0301 basic medicineNeuroblastoma RAS viral oncogene homologOncologyCancer Researchmedicine.medical_specialtytargeted agentsColorectal cancermedicine.medical_treatmentEGFRPopulationPhases of clinical researchcolorectal cancerReviewmedicine.disease_causelcsh:RC254-282meta-analysi03 medical and health sciences0302 clinical medicineInternal medicinemedicineEpidermal growth factor receptoreducationChemotherapyeducation.field_of_studybiologybusiness.industrysequencemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensVEGFmeta-analysis030104 developmental biologyOncology030220 oncology & carcinogenesisMeta-analysisbiology.proteinKRASsecond linebusinessCancers
researchProduct

Discovery of a Pederin Family Compound in a Nonsymbiotic Bloom-Forming Cyanobacterium

2018

The pederin family includes a number of bioactive compounds isolated from symbiotic organisms of diverse evolutionary origin. Pederin is linked to beetle-induced dermatitis in humans, and pederin family members possess potent antitumor activity caused by selective inhibition of the eukaryotic ribosome. Their biosynthesis is accomplished by a polyketide/nonribosomal peptide synthetase machinery employing an unusual trans-acyltransferase mechanism. Here, we report a novel pederin type compound, cusperin, from the free-living cyanobacterium Cuspidothrix issatschenkoi (earlier Aphanizomenon). The chemical structure of cusperin is similar to that of nosperin recently isolated from the lichen cya…

0301 basic medicineNostocSpectrometry Mass Electrospray IonizationMagnetic Resonance SpectroscopyGENE-CLUSTERPAEDERUSpederinsPederinCyanobacteriaBiochemistry03 medical and health scienceschemistry.chemical_compoundPolyketideBiosynthesisNonribosomal peptideTandem Mass SpectrometryCHEMISTRYGene clusterBACTERIAL SYMBIONTBIOSYNTHESISPeptide SynthasesSymbiosissyanobakteeritta116chemistry.chemical_classificationbioactive compoundsbiologybioaktiiviset yhdisteetta1182General Medicinebiology.organism_classificationluonnonaineetnaturally occurring substancesamidesPOLYKETIDE SYNTHASES030104 developmental biologychemistryBiochemistryGenes BacterialMultigene FamilyPolyketidesamiditCyanobiontMolecular Medicine1182 Biochemistry cell and molecular biologyEukaryotic Ribosome
researchProduct

Clinical-pathological characteristics and short-term follow-up associated with proliferation, apoptosis and angiogenesis in a prospective cohort of p…

2019

We investigate the clinical and pathological features related to variations in colorectal tumour apoptosis, proliferation and angiogenesis and the influence of the latter in short-term mortality (2 years); 551 tumour samples from a prospective cohort of patients with colorectal cancer were examined and tumour biology markers were determined as follows: percentage of apoptotic cells, by the terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling technique; Ki-67 antigen, as a cell proliferation marker and density of microvessels (as a marker of angiogenesis). An increase in the percentage of cellular apoptosis is significantly related to the presence of poorly differentiated tumo…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyAngiogenesisApoptosisDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicineBiomarkers TumorMedicineHumansProspective cohort studyPathologicalRC254-282AgedCell ProliferationNeovascularization PathologicCell growthbusiness.industryEndoglinColorectal tumourNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMiddle AgedPrognosis030104 developmental biologyKi-67 AntigenApoptosis030220 oncology & carcinogenesisFemalebusinessColorectal NeoplasmsFollow-Up StudiesTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
researchProduct

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

2020

Simple Summary Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancer (RCC), with no data on its prevalence worldwide. No genotype-phenotype associations have been described. The aim of our study was to describe the genotypic and phenotypic features of the largest series of patients with HLRCC from Spain reported to date. Of 27 FH germline pathogenic variants, 12 were not previously reported in databases. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function varia…

0301 basic medicineOncologyCancer ResearchCancer cellsmedicine.disease_causeurologic and male genital diseases:Male Urogenital Diseases::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Male Urogenital Diseases::Carcinoma Renal Cell [DISEASES]<i>FH</i> gene0302 clinical medicineMalalties hereditàriesMissense mutationFH geneFH gene hereditary leiomyomatosis leiomyomas missense pathogenic variants renal cell cancerRenal cell cancerMutationKidney diseasesHereditary leiomyomatosis:Otros calificadores::Otros calificadores::/genética [Otros calificadores]:enfermedades urogenitales masculinas::neoplasias urogenitales::neoplasias urológicas::neoplasias renales::enfermedades urogenitales masculinas::carcinoma de células renales [ENFERMEDADES]leiomyomasmissense pathogenic variants renal cell cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRare diseases:Geographic Locations::Europe::Spain [GEOGRAPHICALS]Oncology030220 oncology & carcinogenesisCohortCèl·lules cancerosesMalalties raresRenal Cell CancersGenetic disordersmedicine.medical_specialtyMissense pathogenic variantsBiología Celularlcsh:RC254-282Article03 medical and health sciencesLeiomyomasInternal medicine:Other subheadings::Other subheadings::/genetics [Other subheadings]medicineRonyons - Malalties - Espanya:localizaciones geográficas::Europa (continente)::España [DENOMINACIONES GEOGRÁFICAS]business.industry:neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::leiomioma::leiomiomatosis [ENFERMEDADES]Retrospective cohort studymedicine.diseaseGenética030104 developmental biologyFumaraseClinical diagnosisHereditary leiomyomatosis and renal cell cancer syndromeMalalties del ronyó:Neoplasms::Neoplasms by Histologic Type::Neoplasms Connective and Soft Tissue::Neoplasms Muscle Tissue::Leiomyoma::Leiomyomatosis [DISEASES]hereditary leiomyomatosisbusiness
researchProduct

Transcriptomic and Genetic Associations between Alzheimer's Disease, Parkinson's Disease, and Cancer.

2021

Simple Summary Epidemiological studies have identified a link between neurodegenerative disorders and a reduced risk of overall cancer. Increases and decreases in the risk of site-specific cancers have also been reported. However, it is still unknown whether these associations arise due to shared genetic and molecular factors or are explained by other phenomena (e.g., biases in epidemiological studies or the use of medication). In this study, we aimed to investigate the potential molecular, genetic, and pharmacological links between Alzheimer’s and Parkinson’s diseases and a large panel of 22 cancer types. To examine the overlapping involvement of genes and pathways, we obtained differentia…

0301 basic medicineOncologyCancer ResearchParkinson's diseaseGenetic correlationsGenome-wide association studyDiseaseComorbidityParkinson Enfermedad de - Aspectos genéticos.chemistry.chemical_compound0302 clinical medicineExemestaneParkinson's disease - Genetic aspects.MedicineParkinsonCáncer - Aspectos genéticos.Càncer -- Aspectes genèticsRC254-282Alzheimer's disease - Genetic aspects.NeurodegenerationNeoplasms. Tumors. Oncology. Including cancer and carcinogensCódigo genético.comorbidityOncology:Informàtica::Aplicacions de la informàtica::Bioinformàtica [Àrees temàtiques de la UPC]medicine.medical_specialtyGenetic code.Alzheimer Enfermedad de - Aspectos genéticos.Article03 medical and health sciencesInternal medicineParkinson Malaltia dePI3K/AKT/mTOR pathwaygenetic correlationsCancer - Genetic aspects.business.industryCancertranscriptomicmedicine.diseaseComorbidityAlzheimer Malaltia d'030104 developmental biologychemistryTranscriptomicmeta-analysesMeta-analysesNeurodegenerative disordersAlzheimerGene expressionbusiness030217 neurology & neurosurgeryCancers
researchProduct

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

2020

AbstractBackgroundHER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to d…

0301 basic medicineOncologyCancer ResearchReceptor ErbB-2ApoptosisAdo-Trastuzumab EmtansineSettore MED/06chemistry.chemical_compound0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturedskin and connective tissue diseasesAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisGene Expression Regulation NeoplasticSurvival RateOncology030220 oncology & carcinogenesisFemalePertuzumabmedicine.drugT-DM1 efficacymusculoskeletal diseasesAdultmedicine.medical_specialtyHER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacyBreast NeoplasmsAntibodies Monoclonal Humanizedlcsh:RC254-28203 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineBiomarkers TumorHumansneoplasmsAgedCell ProliferationRetrospective StudiesHER2+ breast cancer; T-DM1 efficacy; Trastuzumab/pertuzumab blockadeTaxanebusiness.industryResearchCancerHER2+ breast cancerTrastuzumabmedicine.diseaseTrastuzumab/pertuzumab blockadeBlockadeLog-rank test030104 developmental biologychemistryTrastuzumab emtansineCancer cellbusiness
researchProduct